Objectives: The outcome of patients undergoing aortic valve replacement (AVR) may be affected by the influence of prosthesis -patient mismatch on left ventricular mass regression. However, due to the discrepancies in labeled valve size, size of sizer and actual valve dimension, it is difficult to compare different valve types. In order to perform an objective comparison, this study was designed to compare the hemodynamics of the Edwards Lifescience pericardial (ELP) and the Medtronic Mosaic porcine (MM) bioprosthesis between patients receiving the same valve size and between patients with the same aortic annulus diameter. Methods: This prospective, randomized study was performed on 81 hospital survivors out of 86 patients undergoing AVR with either the ELP ðn ¼ 39Þ or the MM ðn ¼ 42Þ bioprosthesis. Intraoperative randomization was performed after the surgeon had excised the aortic valve, measured the size of the aortic annulus with three different sizers (ELP, MM and a set of metric sizers), and decided which size he would implant for either of the valve types. All valves were implanted in supra-annular position with the same implantation technique. Echocardiographic follow-up was performed early postoperatively and 6 months thereafter. Results: In 12 (31%) of the patients receiving the ELP-valve, as compared to 3 (7.1%) of the patients receiving the MM-valve, the labeled valve size was smaller than the aortic annulus diameter ðP , 0:05Þ: Early postoperatively, mean (17.4^3.1 vs 20.3^3.6 mmHg) and peak gradients (30.1^4.8 vs 37.6^9.6 mmHg) for the 21 mm ELP-valve were lower than for the 21 mm MM-valve ðP , 0:05Þ: All other hemodynamic parameters did not show significant differences at any time point. When the same aortic annulus diameter was taken as a reference, there were no significant hemodynamic differences between either valve type at any time point, regardless of the valve size implanted. Conclusions: This study demonstrates that the hemodynamic performance of the ELP and the MM bioprosthesis are comparable when the same aortic annulus diameter is taken as a reference. The significant variabilities between different valve types with regard to labeled valve size, valve-sizer size and actual valve size have to be taken into account, when hemodynamic comparisons are performed. q
Introduction
Due to the increasing number of older patients requiring aortic valve replacement (AVR) and the persistent risk of thromboembolic and bleeding complications in patients with mechanical prosthesis, the use of biological valve substitutes has continuously increased during recent years. Accordingly, there is a renewed interest in the hemodynamic performance of biological valves, because intermediate and long-term survival may be affected by the influence of prosthesis -patient mismatch on left ventricular mass regression especially in patients with small aortic roots [1 -3] . Hemodynamic comparison of the various available biological valve types, however, is difficult, since substantial discrepancies between industrylabeled valve sizes, dimensions of valve sizers and actual size of the respective valves exist [4, 5] . In order to obtain accurate and clinically relevant data on the hemodynamic performance of different valve types, it is therefore necessary to compare the hemodynamic performance of valve prosthesis in relation to the dimensions of the native aortic annulus and not on the basis of industry-labeled valve size [6 -8] . Since the second generation Edwards Lifescience pericardial (ELP) and the third generation Medtronic Mosaic porcine (MM) bioprosthesis are both designed as supra-annular valve substitutes and have gained widespread use as aortic valve prosthesis, a direct comparison of both valves appears justified.
This study was designed to compare the hemodynamics of both valves between patients with the same industrylabeled valve size and between patients with the same diameter of the aortic annulus in a prospective, randomized fashion. The results of this investigation should help surgeons to choose the optimal valve substitute for the individual patient.
Patients and methods

Patients
This prospective, randomized study was performed on 86 patients (age range 54 -79 years). For data analyses 81 hospital survivors were included. All patients underwent AVR with either the ELP (n ¼ 39) or the MM (n ¼ 42) bioprosthesis. Exclusion criteria included emergency surgery, age , 19 and . 80 years, left ventricular ejection fraction , 25%, reoperative procedures of any type, multiple valve replacement or other concomitant procedures other than coronary artery bypass grafting (CABG), endocarditis, and co-existent illness known to have a high mortality. The study was approved by the hospital ethics committee and written informed consent was obtained from all patients before inclusion.
Operative technique
All operations were performed by a total of four staff surgeons, using complete or partial median sternotomy and standard cardiopulmonary bypass techniques, including systemic normo-or mild hypothermia and cold ante-and retrograde blood cardioplegia. Distal anastomoses in patients undergoing additional coronary artery bypass grafting were performed before AVR. Intra-operative randomization was performed after the surgeon had excised the aortic valve, decalcified the aortic annulus if necessary, measured the size of the annulus with three different sizers (ELP, MM and a standard set of intra-annular, cylindricalshaped metric sizers with diameters of 19, 21, 23, 25, 27, and 29 mm), and decided which valve size he would implant for either of both valve types. With regard to sizing with the metric sizers, the surgeons were instructed to determine the largest size that just slips through the annulus without applying any force and without dilating the annulus. All valves were implanted in supra-annular position using the same technique of multiple, vertical mattress sutures, reinforced by subannular polytetrafluoroethylene felts and allowing the prosthesis to sit on top of the annulus.
Echocardiographic assessement
Transthoracic Doppler echocardiographic evaluation was performed between postoperative days 8-12 and at 6 months postoperatively. Standard parasternal and apical views were obtained. The following parameters were measured: left ventricular enddiastolic and endsystolic diameters, thickness of the posterior wall and the interventricular septum, ejection fraction, ejection time, maximum and mean flow velocities across the valve and in the left ventricular outflow tract. Using standard equations the following calculations were performed: peak and mean transvalvular gradients, prosthetic valve effective orifice area, and left ventricular muscle mass.
Statistical analysis
All measurements were log transformed because of a right-skewed distribution and an analysis of variance was applied to test differences between the three aortic sizers. Pairwise comparisons were calculated and P-values were adjusted for multiple comparison by the method of Dunnett. The resulting least-square means and corresponding 95% confidence intervals were transformed back on the original scale.
Results
The follow-up at 6 months was 100% complete for all 81 hospital survivors included in the study. Demographic and surgical data of those patients are given in Table 1 . The number of implanted valves with regard to valve type and labeled valve size is given in Table 2 . In 12 (31%) of the patients receiving the ELP-valve, as compared to only 3 (7.1%) of the patients receiving the MM-valve, the implanted labeled valve size was smaller than the assessed aortic annulus diameter ðP , 0:05Þ: All three of the MMdownsized patients, however, were in the 27 mm aortic annulus-group, whereas all 12 ELP-downsized patients belonged to the 21, 23, and 25 mm aortic annulus-group. In addition, 3 (7.1%) of the MM-patients but none of the ELPpatients received valves with labeled valve sizes larger than the aortic annulus diameter.
All hemodynamic data including mean and peak transvalvular gradient, effective orifice area early postoperative and after 6 months and regression of left ventricular mass after 6 months according to industrylabeled valve sizes of both valve types are listed in Tables 3  and 4 . No MM-19 mm valves were implanted. Mean and peak gradients for the ELP-labeled valve sizes 21, 23, and 25 mm were slightly lower than for the comparable MMvalves. This difference was significant for the 21 mm valves only. All other hemodynamic parameters were comparable. Interestingly, the reduction in left ventricular muscle mass for the 10 implanted 19 mm ELP-valves was substantially lower than for all other valves sizes of both valve types, indicating a possible prosthesis -patient mismatch in this subgroup. However, these patients did not show an increased incidence of postoperative clinical complications and/or events. In addition, there were no significant differences in the NYHA-class functional status at 6 months postoperatively (1.91 for the 10 patients receiving the 19 mm ELP-valve vs. 1.85 for all other patients, n.s.).
Hemodynamic data for both valve types in relation to the aortic annulus diameter are presented in Tables 5 and 6 . When the same aortic annulus diameter was taken as a reference, there were no significant hemodynamic differences between either valves early postoperatively or at 6 month follow-up. Since only one patient with a 19 mm annulus was randomized to the MM-valve cohort (receiving a 21 mm valve), no comparison between both valves types was possible in this annulus diameter group. However, the hemodynamic data of this patient were included in the labeled valve size analysis.
None of the investigated valve sizes of either valve type demonstrated any significant difference of hemodynamic parameters between the early and 6 months postoperative evaluation.
Discussion
Mid-and long-term results of second-and third generation biological bioprosthesis with regard to structural deterioration and need for early reoperation are encouraging. The advantages of biological bioprosthesis compared to mechanical prosthesis also include a lower risk of thromboembolism and anticoagulant-related hemorrhage. Those factors have contributed to the more liberal indications for the use of biological aortic valve substitutes including patients under 70 years of age. Whereas the question of structural durability of currently used biological valves appears to decline as the main factor in the surgeon's choice for the ideal valve substitute in the individual patient, the issue of hemodynamic performance of the respective prosthesis has gained increased consideration.
Various studies have shown that the hemodynamic performance of aortic valve prosthesis does have a substantial impact on the influence of prosthesis -patient mismatch on ventricular mass regression and, consequently, mid-and long-term survival especially in patients with small aortic roots [1, 3] . Among many other factors, such as stent size and flexibility, compliance characteristics of sinuses, extent of annulus decalcification, positioning of the valve, etc. the most important determinant of postoperative valve hemodynamics is the internal diameter of the implanted valve [7] . However, the surgeon's goal to implant the largest possible prosthesis in the individual patient is hampered by the fact that there are surprising discrepancies between the industry-labeled valve and valve-sizer dimensions and the actual internal and external diameter of the respective valves. The internal diameters as reported by the manufacturers of both biological valves used in this study (ELP, MM), f.e., differ by up to 2 mm per industry-labeled valve size, which makes the direct, prosthesis size-related comparison of both valves difficult [9] .
The current study evaluated the hemodynamic performance of both valves in relation to the industry-labeled valve size and the actual inner diameter of the aortic annulus. This comparison was possible due to the fact that both valves are designed for supra-annular implantation and, in addition, were implanted with the identical surgical technique, which was used by all four surgeons in the study.
Both valves used in this randomized trial have an impressive track record with regard to valve-related complications such as thromboembolism, hemorrhage or incidence of endocarditis [10 -13] . Whereas the ELPvalve has also been demonstrated to have a low incidence of structural deterioration over more than 15 years after implantation, only mid-term follow-up data are available for the MM porcine bioprosthesis [14, 15] . However, since its direct predecessor, the Hancock II porcine bioprosthesis, has shown long-term follow-up data comparable to those of the ELP-valve, it appears realistic to assume that the incorporation of new tissue valve technologies such as zero-pressure fixation and alpha amino oleic acid antimineralization treatment to the Mosaic design will provide at least similar long-term outcome [16] .
The results of our study indicate that the overall hemodynamic performance of both valves was comparable only when their performance was related to the inner diameter of the aortic annulus and not to the implanted industry-labeled valve size. The clinical relevance of this assessment is also confirmed by the fact that the amount of left ventricular mass reduction after 6 months was similar and substantial in both groups when annulus diameters of 21 mm and more were compared. This comparison was not possible for annulus sizes of 19 mm, since only one patient with a 19 mm annulus size was randomized to the MMvalve group. These data also indicate that the good hemodynamic performance of both valve types avoided a prosthesis -patient mismatch in patients with an aortic annulus diameter of at least 21 mm. The satisfactory hemodynamic performance of both valves also support conclusions from studies by Milano [6] and Rao [8] , indicating that biological valves of the second and third generation may even parallel the hemodynamic performance of stentless valves when the comparison of both valve types is performed between patients with the same aortic annulus diameter.
Our data clearly show, however, that the ELP-valve does have a hemodynamic advantage, when industry-labeled sizes of the implanted valves are compared, especially in patients with labeled valve sizes of 21 and 23 mm. This can easily be explained by the fact that the size-matched manufacturer-reported internal diameter of the ELP-valve is between 1.5 and 2 mm larger than the respective manufacturer-reported internal diameter of the MM-valve [9] . However, the surgeon's decision on the maximum possible implantable valve size entirely depends on the information given to him by sizing the aortic annulus with the sizers provided by the manufacturers. Since the outer diameter of the intra-annular portion of the ELP-sizer is almost 1.5 mm larger than a size-matched MM-sizer (data provided by both companies), it is easy comprehendable that our data demonstrate a significant tendency to implant smaller ELP-than MM-valves in relation to the inner diameter of the aortic annulus. This difference eventually erased the hemodynamic advantage of the size-related larger internal diameter of the ELP-valve.
The hemodynamic analysis of both valve types, however, also indicates that although patients receiving a 19 mm ELP-valve do have reasonable low valve gradients, there is only a small reduction in left ventricular muscle mass after 6 months. It cannot be concluded from our data whether these observations are due to a prosthesis -patient mismatch or may be explained by the relatively short follow-up period of 6 months [17] . The lack of left ventricular muscle mass reduction, however, did not translate in any obvious functional disadvantage, as is demonstrated by the fact that the analysis of the NYHA-class functional status at 6 months postoperatively did not reveal any significant differences when compared to patients receiving larger valve sizes. Nevertheless, since comparable data for 19 mm MM-valves are not available, the possible advantage of aortic root enlargement rather than implantation of a 19 mm ELP-valve should be considered.
This study was designed to evaluate possible hemodynamic differences of often-used biological valves under realistic clinical conditions. Consequently, the design of the study is certainly not free of shortcomings that may have affected study results and the interpretation of those results. The fact that we used the identical implantation technique for both valves may or may not have benefited one of the valve types used. However, since there are no conclusive data available that may prove a hemodynamic advantage of a certain implant technique for either valve, this decision was based on the fact that both valves were designed for supra-annular implantation and, consequently, can be implanted by the same technique without an obvious disadvantage for one of them. The fact that the operations were performed by four different surgeons also might have influenced the outcome of the study. It does, however, reflect the every day practice in most cardiac centers, where the same valve prosthesis are implanted by different surgeons. In our study, all surgeons had to perform the valve sizing before they knew which prosthesis they had to implant, thereby minimizing the influence of possible valve preferences of the individual surgeon. However, valve sizing itself is a mechanical event that depends on many factors including issues that may vary from surgeon to surgeon such as extent of annulus decalcification, sizing experience or bias. The design of this study certainly cannot totally exclude the influence of those surgeon-related factors on choosing the maximal possible valve size.
In conclusion, our study clearly demonstrates that the hemodynamic performance of prosthetic valve substitutes cannot be compared on the basis of industry-labeled valve sizes but should always be related to the inner diameter of the aortic annulus, a parameter that can easily be assessed intra-operatively. Each surgeon must be aware of significant variabilities with regard to the relation of labeled valve size, valve-sizer size and actual internal and external valve diameters not only between different valves but also within the same valve type. With regard to the ELP and MM prosthesis tested in this study, however, the significant discrepancies of those parameters in both valves erased each other at least when their hemodynamics were related to the diameter of the aortic annulus. In this respect, implantation of either valve provides relatively low gradients and significant reduction of left ventricular muscle mass when labeled valve sizes of 21 mm or more are used.
